查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2024982

鐮狀細胞疾病治療市場報告：按治療方法、最終用戶和地區分類的市場規模、佔有率、趨勢和預測（2026-2034 年）

Sickle Cell Disease Treatment Market Report Size, Share, Trends and Forecast by Treatment Type, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球鐮狀）治療市場規模為46億美元。預計到2034年，該市場規模將達到138億美元，2026年至2034年的複合年成長率（CAGR）預計為12.73%。北美目前在該市場中佔據主導，2025年市佔率高達38.7%。推動該市場成長的主要因素是全球鐮狀細胞病患疾病率的上升，這得益於新生兒篩檢計畫的擴展和診斷能力的提高。此外，研發投入的增加以及基因和細胞療法的進步正在加速創新治療方法的推出。同時，政府支持政策、醫療保健支出的增加以及各項舉措也是推動鐮狀細胞疾病治療市場佔有率成長的關鍵因素。

該市場的主要驅動力是發展中地區先進醫療基礎設施的建設以及用於遠端監測和患者管理的數位健康工具的普及。例如，加州大學聖地牙哥分校開發了一個基於電子健康記錄(EHR) 的自動化登記系統，用於在其醫療系統中識別鐮狀細胞疾病 (SCD) 患者，截至 2024 年 7 月，該系統的陽性預測率達到了 92.6%。此登記系統可識別出 31 例確診的 SCD 患者，並啟動了旨在改善醫療服務可近性的外展工作。除了識別患者外，此登記系統還用於監測臨床品質指標、追蹤再入院情況以及支援護理協調。此外，公共衛生機構與私人企業之間日益密切的合作正在改善患者獲得專科治療的機會。高發生地區臨床試驗網路的擴展正在加速開發針對特定區域的治療方案。最後，對個人化醫療的日益重視正在推動基因譜分析在指導治療方法選擇方面的應用。

在美國，政府高度重視醫療保健公平，致力於改善受鐮狀（ Sickle Cell Disease）影響尤為嚴重的群體獲得醫療保健服務的機會。根據2024年的行業報告，美國有超過10萬人患有鐮狀細胞疾病。鐮狀鐮狀疾病治療市場的一大趨勢是聯邦政府加大對相關研究的投入，加速創新治療方法的研發。此外，擁有多學科專家的專科治療中心的存在，確保了疾病的全面管理。電子健康記錄的廣泛應用也促進了協調護理和持續監測。學術機構與生技公司之間日益密切的合作，推動了根治性方法的突破性進展。此外，針對先進療法的優惠報銷政策，也提高了療法的普及率，並鞏固了美國在鐮狀細胞疾病創新和醫療保健領域的領先地位。

鐮狀細胞疾病治療市場的發展趨勢：

鐮狀細胞疾病（SCD）患者數量增加

鐮狀細胞疾病（鐮狀）的全球盛行率正在穩步上升，這主要受高發地區人口成長、生存率提高以及新生兒篩檢計畫擴展（導致更多病例在出生時被發現）的影響。例如，到2025年，全球將有超過2,000萬人患有鐮狀，其中超過10萬人居住在美國。人口遷移趨勢也加劇了疾病的地理傳播，增加了SCD先前罕見地區的治療需求。此外，儘管醫療保健的進步延長了患者的平均壽命，但也意味著醫療系統必須管理更多患有慢性併發症的患者。患者數量的增加也使得多樣化的治療方案（包括根治性和支持性療法）的需求日益成長。為了應對不斷上升的盛行率，各國政府、研究機構和醫療服務提供者正在加快資源投入、擴大治療基礎設施並開發創新治療方法，以滿足不斷成長的患者群體不斷變化的需求。

可支配所得增加和個人意識提高

可支配收入的成長，尤其是在新興經濟體，使得更多鐮狀細胞疾病（SCD）患者能夠及時獲得先進的治療。這推動了鐮狀細胞疾病治療市場的成長。根據產業報告預測，到2025年5月，美國個人可支配收入（DPI）預計將達到22.4546兆美元。隨著人們經濟狀況的改善，他們更有可能獲得專業的醫療服務，定期進行診斷檢查，並將資金用於長期治療方案，包括緩解疾病藥物和基因療法等昂貴的治療方法。同時，政府主導的宣傳活動、互助小組和教育計畫提高了公眾對鐮狀細胞疾病的認知。公共衛生舉措正在傳播有關早期症狀、預防措施和現有治療方法的訊息，從而實現早期診斷和更有效的疾病管理。此外，知識的普及也促使患者更積極參與臨床試驗並接受新的治療方法。經濟實力的增強和意識的提高，使得尋求治療的患者群體顯著擴大，刺激了對現有 SCD治療方法和創新治療方法的市場需求。

衛生監理機關加速核准

全球監管機構正日益重視加速創新治療方法的核准流程。這一趨勢提振了鐮狀）治療市場的前景。例如，2019年，美國食品藥物管理局（FDA）核准了一種用於緩解成人和兒童鐮狀患者疼痛的新藥。這一轉變源於迫切需要解決該疾病帶來的沉重負擔以及現有治療方法的局限性。優先審查、突破性治療方法認定和孤兒藥認定等機制正被應用於前景看好的藥物、基因療法和先進細胞療法。這些加速核准流程縮短了從臨床開發到上市的時間，使患者能夠更早獲得可能改變生活的治療方法。監管機構也在加強與研發公司的合作，並就試驗設計、安全方案和生產標準提供早期指導，以確保合規性並維持高安全標準。這種積極主動的做法不僅支持創新，還鼓勵對研發進行更多投資，使公司能夠更快地獲得投資回報並降低研發風險。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球鐮狀細胞疾病治療市場報告

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療類型分類

  • 輸血
  • 藥物治療
  • 骨髓移植

第7章 市場區隔：依最終用戶分類

  • 醫院
  • 診斷中心
  • 其他

第8章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章 SWOT 分析

第10章：價值鏈分析

第11章：波特五力分析

第12章：價格分析

第13章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AstraZeneca Plc
    • Baxter International Inc.
    • bluebird bio Inc.
    • Bristol-Myers Squibb Company
    • CRISPR Therapeutics
    • Emmaus Medical Inc.
    • Global Blood Therapeutics Inc.
    • GlycoMimetics Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sangamo Therapeutics
Product Code: SR112026A4076

The global sickle cell disease treatment market size was valued at USD 4.6 Billion in 2025. The market is expected to reach USD 13.8 Billion by 2034, exhibiting a CAGR of 12.73% during 2026-2034. North America currently dominates the market, holding a significant market share of around 38.7% in 2025. The market is fueled by the rising prevalence of sickle cell disease globally, supported by expanding newborn screening programs and improved diagnostic capabilities. Besides that, growing investments in research and development, alongside advancements in gene and cell therapies, is accelerating the availability of innovative treatment options. In addition to this, supportive government policies, increased healthcare funding, and initiatives are significant factors augmenting the sickle cell disease treatment market share.

The market is majorly influenced by the increasing availability of advanced healthcare infrastructure in developing regions and the integration of digital health tools for remote monitoring and patient management. For instance, the University of California San Diego developed an automated electronic health record-based registry to identify sickle cell disease (SCD) patients across its health system, achieving a 92.6% positive predictive value, as of July 2024. The registry identified 31 confirmed SCD patients, with targeted outreach initiated to improve care access. Beyond patient identification, the registry is being used to monitor clinical quality metrics, track readmissions, and support care coordination. Moreover, rising collaborations between public health organizations and private entities are enhancing access to specialized treatments. Besides that, expanding clinical trial networks in high-prevalence areas are accelerating the development of region-specific therapeutic solutions. Also, growing emphasis on personalized medicine is encouraging the use of genetic profiling to guide treatment selection.

In the United States, there strong focus on health equity initiatives to improve care access for communities disproportionately affected by sickle cell disease. As per industry reports in 2024, SCD has affected over 100,000 individuals in the United States. One of the significant sickle cell disease treatment market trends is the expansion of federal funding for research, which enables accelerated progress in innovative therapies. In addition to this, the presence of specialized treatment centers with multidisciplinary expertise ensures comprehensive disease management. Moreover, widespread adoption of electronic health records is facilitating coordinated care and continuous monitoring. Increasing partnerships between academic institutions and biotechnology firms are fostering breakthroughs in curative approaches. Additionally, favorable reimbursement frameworks for advanced treatments are supporting higher adoption rates, reinforcing the country's leadership in sickle cell disease innovation and care delivery.

SICKLE CELL DISEASE TREATMENT MARKET TRENDS:

Increase in the Number of Individuals Suffering from SCD

The global prevalence of sickle cell disease is steadily increasing, driven by population growth in high-burden regions, improved survival rates, and expanded newborn screening programs that identify more cases at birth. For instance, in 2025, over 20 Million individuals worldwide suffer from the SCD disorder, with over 100,000 of these patients living in the USA. Migration patterns are also contributing to a broader geographic spread of the disease, leading to increased demand for treatment in areas where SCD was previously uncommon. Besides this, advances in medical care have improved life expectancy for patients, but this also means that the healthcare system must manage a larger number of individuals living with chronic complications. Also, the growing patient base intensifies the need for diversified treatment options, including both curative and supportive care approaches. This rising prevalence is prompting governments, research institutions, and healthcare providers to strengthen resources, expand treatment infrastructure, and accelerate the development of innovative therapies to meet the evolving needs of the expanding patient population.

Rising Disposable Incomes and the Growing Awareness among Individuals

Increasing disposable incomes, particularly in emerging economies, are enabling more patients to seek timely and advanced treatment for sickle cell disease (SCD). This, in turn, is supporting the sickle cell disease treatment market growth. As per industry reports, in the United States, disposable personal income (DPI) in May 2025 was USD 22,454.6 Billion. As financial capacity improves, individuals are more likely to access specialized healthcare facilities, undergo regular diagnostic testing, and afford long-term treatment plans, including higher-cost therapies such as disease-modifying drugs or gene-based interventions. This trend is complemented by growing awareness of SCD through government-led campaigns, advocacy groups, and educational programs. Public health initiatives are disseminating information on early symptoms, preventive measures, and available treatments, leading to earlier diagnoses and more effective disease management. Besides, enhanced knowledge has also resulted in greater patient engagement, with individuals more willing to participate in clinical trials and adopt new therapies. Together, improved financial means and heightened awareness are significantly expanding the treated patient pool, stimulating market demand for both existing and innovative SCD treatments.

Fast-track Approvals by Health Regulatory Authorities

Regulatory agencies in various countries are increasingly prioritizing accelerated pathways for the approval of innovative treatments. This trend is creating a positive sickle cell disease treatment market outlook. For instance, the United States Food and Drug Administration (USFDA) approved a new medicine in 2019 to reduce the pain experienced by adults and children with SCD. This shift is driven by the urgent need to address the significant disease burden and the limitations of existing therapeutic options. Mechanisms such as priority review, breakthrough therapy designation, and orphan drug status are being applied to promising drugs, gene therapies, and advanced cell-based interventions. These expedited processes reduce the time between clinical development and market availability, enabling patients to access potentially life-changing treatments sooner. Regulatory bodies are also enhancing collaboration with developers to provide early guidance on trial design, safety protocols, and manufacturing standards, ensuring compliance while maintaining high safety benchmarks. This proactive approach not only supports innovation but also encourages greater investment in research, as companies can anticipate faster returns and reduced development risk.

SICKLE CELL DISEASE TREATMENT INDUSTRY SEGMENTATION:

Analysis by Treatment Type:

  • Blood Transfusion
  • Pharmacotherapy
  • Bone Marrow Transplant

Blood transfusion leads the market with around 48.9% of market share in 2025. This type of treatment is one of the most widely used and accessible interventions. It helps reduce the proportion of sickled red blood cells, improving oxygen delivery and lowering the risk of severe complications such as stroke and organ damage. Transfusions are particularly important in managing acute episodes and preventing recurrent crises in high-risk patients. They are also used as a long-term preventive measure for children and adults with severe disease manifestations. While effective, regular transfusions require careful monitoring to manage risks like iron overload and transfusion reactions, which has led to the parallel growth of iron chelation therapies. In regions with limited access to advanced treatments, blood transfusion remains a cornerstone of care, reinforcing its continuing relevance in both developed and resource-constrained healthcare systems.

Analysis by End User:

  • Hospitals
  • Diagnostic Centers
  • Others

Hospitals lead the market with around 60.8% of market share in 2025. Hospitals are the leading centers for diagnosis, management, and specialized care. They offer holistic services, which range from emergency interventions for pain crises to administration of blood transfusions and monitoring for complications such as stroke or organ damage. Hospitals are also the main locations for specialized interventions such as stem cell transplants and gene therapy, which need sophisticated infrastructure and multidisciplinary capabilities. Additionally, they have specialized hematology departments and laboratories for ongoing monitoring of patients and management of diseases. They also play a role in patient education, counseling, and coordination of long-term care. In most areas, hospitals serve as referral centers, connecting patients with clinical trials and new treatments. Their capacity to provide both acute and preventive care makes them an important end-user segment, with direct effects on treatment accessibility, quality, and patient outcomes within the market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 38.7% due to its advanced healthcare infrastructure, high disease awareness, and strong research capabilities. The region benefits from established screening programs, early diagnosis, and access to a broad range of treatment options, from supportive care to cutting-edge gene and cell therapies. Significant investment in clinical research and favorable regulatory pathways support the rapid introduction of new therapies, making the region a leader in innovation. Insurance coverage and government-funded healthcare programs improve access for many patients, though disparities persist among underserved populations. The presence of specialized treatment centers and experienced healthcare professionals ensures high-quality care and ongoing monitoring. With continuous advancements and growing adoption of novel treatments, North America remains a critical market, influencing global trends and driving the pace of therapeutic development for sickle cell disease.

KEY REGIONAL TAKEAWAYS:

UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS

In 2025, the United States holds a substantial share of around 89.00% of the sickle cell disease treatment share in North America. United States has witnessed increasing sickle cell disease treatment adoption due to the expansion of diagnostic centers across urban and rural areas. For instance, there are 32,257 businesses in the Diagnostic & Medical Laboratories industry in the United States, which has grown at a CAGR of 4.9 % between 2020 and 2025. The presence of advanced diagnostic facilities has improved early detection and monitoring of sickle cell complications, resulting in more timely therapeutic interventions. These diagnostic centers are equipped with modern tools for genetic screening and hemoglobin electrophoresis, which have made diagnosis more efficient and accessible. Moreover, rising awareness among patients and healthcare professionals about early testing is encouraging regular screenings. Insurance coverage for diagnostic procedures has further contributed to increased utilization of sickle cell treatments. Healthcare systems are increasingly integrating these services into primary care networks, ensuring faster referrals and treatment decisions.

ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS

Asia-Pacific is experiencing rising adoption of sickle cell disease treatment driven by a noticeable surge in anemia cases across both urban and rural populations. According to Ministry of Health and Family Welfare (MoHFW) (April 2025) indicates that 67.1% of children and 59.1% of adolescent girls are anemic. Increasing awareness regarding hereditary blood disorders and rising anemia prevalence have prompted more individuals to seek medical evaluation for underlying hemoglobinopathies. Healthcare providers are responding by incorporating advanced therapeutic protocols aimed at managing sickle cell complications alongside anemia symptoms. Government health programs are also emphasizing screening initiatives that identify anemia cases potentially linked to sickle cell conditions. In rural areas, community outreach programs are facilitating diagnosis and early treatment. This increasing burden of anemia has highlighted the necessity for tailored interventions and disease management strategies.

EUROPE SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS

The market in the Europe is growing due to several factors, including the Rare Diseases Plan implemented in 2017 within the EU, which significantly enhanced the treatment landscape for rare diseases. This initiative, along with the establishment of 24 European Reference Networks (ERNs), including the ERN on Rare Haematological Diseases (ERN-EuroBloodNet), has fostered increased collaboration among healthcare providers, researchers, and patient organizations. This network focuses specifically on rare blood-related conditions like sickle cell disease, promoting the exchange of knowledge, clinical expertise, and resources across European countries. Furthermore, the growing awareness of the disease and its impact on public health is driving initiatives in several European countries. Collaborative efforts between healthcare providers and non-governmental organizations have also led to improvements in early diagnosis and patient management.

LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS

Latin America has observed a notable increase in sickle cell disease treatment adoption due to improvements in healthcare infrastructure. In countries such as Brazil and Mexico, the government and healthcare systems are focusing on raising awareness about the disease and providing essential healthcare services. Available and extrapolated data indicate that sickle cell disease (SCD) affects more than 6,000 newborns annually and between 100,000 and 150,000 individuals across Latin America. Support from international organizations, including the Pan American Health Organization (PAHO), is also helping improve access to therapies and early diagnosis. The increasing availability of clinical trials for new treatments in Latin America is another significant factor fueling market growth in the region. Privatization is also driving innovation and investment in disease-specific care, including sickle cell therapies. As public-private partnerships expand, more individuals are gaining access to advanced medical services, supporting early diagnosis and sustained treatment for sickle cell complications.

MIDDLE EAST AND AFRICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS

Middle East and Africa are experiencing rising sickle cell disease treatment adoption as a result of improved healthcare facilities across several regions. For instance, in 2025, the UAE is currently home to over 150 hospitals and has more than 5,000 healthcare facilities. Moreover, investments in new hospitals, clinics, and hematology units have allowed for better disease management and specialized care. Apart from that, expanded access to professional healthcare staff and modern diagnostic tools is accelerating timely treatment. In addition to this, as per industry reports, Africa carries the greatest burden of sickle cell disease (SCD), with prevalence reaching up to 3% of births in certain regions. This high incidence is driving market growth across the continent.

COMPETITIVE LANDSCAPE:

The market is characterized by rapid innovation, with therapies addressing both symptom control and curative potential. Existing options include supportive care, transfusions, and pharmacological agents aimed at reducing complications. Moreover, advancements in genetic and cell-based therapies are intensifying competition, as these approaches aim to correct the root cause of the disease. Market players are differentiating through safety, efficacy, and delivery methods to reduce treatment burden and improve quality of life. In addition to that, regulatory incentives and expanded clinical research pipelines are accelerating product development, though high costs and limited infrastructure in some regions pose adoption challenges. Competition is also influenced by efforts to expand access in underserved populations through targeted healthcare programs. According to the sickle cell disease treatment market forecast, rising disease awareness, improved diagnostic capabilities, and growing investment in advanced therapeutics are expected to drive strong growth over the next decade, with significant opportunities emerging in both established and resource-limited healthcare systems.

The report provides a comprehensive analysis of the competitive landscape in the sickle cell disease treatment market with detailed profiles of all major companies, including:

  • AstraZeneca Plc
  • Baxter International Inc.
  • bluebird bio Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics
  • Emmaus Medical Inc.
  • Global Blood Therapeutics Inc.
  • GlycoMimetics Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sangamo Therapeutics

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the sickle cell disease treatment market?

2. What is the future outlook of the sickle cell disease treatment market?

3. What are the key factors driving the sickle cell disease treatment market?

4. Which region accounts for the largest sickle cell disease treatment market?

5. Which are the leading companies in the global sickle cell disease treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Sickle Cell Disease Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Blood Transfusion
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Pharmacotherapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bone Marrow Transplant
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Diagnostic Centers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AstraZeneca Plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Baxter International Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 bluebird bio Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bristol-Myers Squibb Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 CRISPR Therapeutics
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Emmaus Medical Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Global Blood Therapeutics Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 GlycoMimetics Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Novartis AG
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sangamo Therapeutics
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Sickle Cell Disease Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Sickle Cell Disease Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Sickle Cell Disease Treatment Market: Breakup by Treatment Type (in %), 2025
  • Figure 5: Global: Sickle Cell Disease Treatment Market: Breakup by End User (in %), 2025
  • Figure 6: Global: Sickle Cell Disease Treatment Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Sickle Cell Disease Treatment (Blood Transfusion) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Sickle Cell Disease Treatment (Blood Transfusion) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Sickle Cell Disease Treatment (Pharmacotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Sickle Cell Disease Treatment (Pharmacotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Sickle Cell Disease Treatment (Bone Marrow Transplant) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Sickle Cell Disease Treatment (Bone Marrow Transplant) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Sickle Cell Disease Treatment (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Sickle Cell Disease Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Sickle Cell Disease Treatment (Diagnostic Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Sickle Cell Disease Treatment (Diagnostic Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Sickle Cell Disease Treatment (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Sickle Cell Disease Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: North America: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: North America: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: United States: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: United States: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Canada: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Canada: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Asia-Pacific: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Asia-Pacific: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: China: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: China: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Japan: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Japan: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: India: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: India: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: South Korea: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: South Korea: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Australia: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Australia: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Indonesia: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Indonesia: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Others: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Others: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Europe: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Europe: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Germany: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Germany: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: France: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: France: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: United Kingdom: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: United Kingdom: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Italy: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Italy: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Spain: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Spain: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Russia: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Russia: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Others: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Others: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Latin America: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Latin America: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Brazil: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Brazil: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Mexico: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Mexico: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Others: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Others: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Middle East and Africa: Sickle Cell Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Middle East and Africa: Sickle Cell Disease Treatment Market: Breakup by Country (in %), 2025
  • Figure 67: Middle East and Africa: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Global: Sickle Cell Disease Treatment Industry: SWOT Analysis
  • Figure 69: Global: Sickle Cell Disease Treatment Industry: Value Chain Analysis
  • Figure 70: Global: Sickle Cell Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Sickle Cell Disease Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Sickle Cell Disease Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 3: Global: Sickle Cell Disease Treatment Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 4: Global: Sickle Cell Disease Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 5: Global: Sickle Cell Disease Treatment Market: Competitive Structure
  • Table 6: Global: Sickle Cell Disease Treatment Market: Key Players